Mutation Spectrum and Genotype–Phenotype Correlation in a Cohort of Argentine Patients with Ornithine Transcarbamylase Deficiency: A Single-Center Experience

Abstract

X-linked ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle disorder. Hemizygous males with complete deficiency manifest neonatal acute hyperammonemia, while those with partial deficiency have a late presentation. The symptomatology of heterozygotes depends on the inactivation pattern of X chromosome. Hyperammonemic episodes can cause neurological damage and are potentially fatal. Here, we match clinical, biochemical, and molecular findings with bioinformatics analyses to report genotype-phenotype correlations in 14 Argentine patients with OTCD from 11 unrelated families: 4 hemizygotes with neonatal onset (complete OTC gene deletion, 533C > T, c.540+1G > A, c.697delG); 4 hemizygotes with late onset (c.216+1G > A, c.386G > A, c.622G > A, c.829C > T); and 6 symptomatic heterozygotes (complete OTC gene deletion, c.533C > T, c.452T > G, c.540+1G > A, dupE1-9/delE10). Three of these mutations were previously unreported: c.540+1G > A, c.697delG, and dup1-9/del10. Our data highlight the relevance of combining molecular and bioinformatics analyses for accurate diagnosis and outcome prediction in suspected patients with OTCD and the importance of carrier testing for effective genetic counseling.

Keywords
urea cycle disorders; ornithine transcarbamylase deficiency; OTC deficiency; OTC mutations; hyperammonemia

Introduction

Ornithine transcarbamylase (OTC; EC 2.1.3.3) catalyzes the formation of citrulline and inorganic phosphate from carbamyl phosphate and ornithine in the urea cycle.¹ The human OTC gene is located on the short arm of the X chromosome (Xp11.4; https://www.omim.org/entry/300461). The OTC enzyme is expressed almost exclusively in the liver and intestinal mucosa, but full activity of the urea cycle occurs only in the liver.

Ornithine transcarbamylase deficiency (OTCD; MIM#311250), an X-linked disease, is the most frequent hereditary defect of ureagenesis with an estimated incidence of 1:56 500 newborns per year in the United States.² Hemizygotes with complete OTCD present acute hyperammonemia in the first week of life, while males with partial deficiency have a late presentation, sometimes in adulthood.³ The severity of OTCD symptoms in women depends mainly on the pattern of X inactivation in the liver, and it ranges from asymptomatic to almost as severe as in affected males.⁴

In general, the clinical signs and symptoms are caused by the toxic effects of hyperammonemia and glutamine in central nervous system. Patients may present lethargy, vomiting, neurological, and behavioral abnormalities and in the most severe cases, cerebral edema, coma, and death. Biochemical abnormalities include hyperammonemia, increased plasma glutamine and decreased or absent citrulline, and increased urinary orotic acid, although these last 2 findings are not always manifested or detected. Carrier identification is very important as it allows timely genetic counseling, thus minimizing the risk of potentially fatal hyperammonemic crisis.⁵

Therapeutic approaches to urea cycle defects, including OTCD, rely on ammonia scavengers (sodium benzoate and sodium phenylbutyrate) in combination with nutritional therapy (low-protein diet, arginine, or citrulline supplementation). Meanwhile, hemodialysis or peritoneal dialysis is used in cases of severe hyperammonemia (>500 µmol/L in neonates and children; >200 µmol/L in adults). In some patients, liver transplantation is also considered.⁶

To date, a total of 504 disease-causing mutations in the OTC gene have been reported in the literature⁷ or registered in the Human Gene Mutation Database (www.hgmd.org). Mutations that block the enzyme’s catalytic action are invariably associated with acute neonatal hyperammonemia, while those that allow residual activity may manifest over a wide age range, from the neonatal period to late adulthood. Phenotypic heterogeneity is observed for mutations that preserve residual activity of the enzyme, even among members of the same family; the cause of this is still not well understood and seems to be due to a combination of genetic factors and environmental variables such as infections or other causes of catabolic stress. Bioinformatic analysis of mutations using in silico strategies is used in OTCD and other genetic diseases to predict severity.

In the current study, we matched clinical data with molecular, biochemical, and bioinformatic analyses to perform a genotype–phenotype correlation analysis of OTC mutations found in patients with OTCD from Argentina diagnosed at a single center (CEMECO, Children’s Hospital of Córdoba).

Patients and Methods

We performed a descriptive, comparative, and correlational study of patients diagnosed with OTCD in CEMECO, Children’s Hospital of the Santísima Trinidad de Córdoba, between 1990 and 2017.

Biochemical analyses included determination of amino acids⁸ and urinary orotic acid⁹ by high-performance liquid chromatography and measurement of plasma ammonia by spectrophotometry (Ammonium Kit, Randox Laboratories LTD, United Kingdom).

The OTC gene mutations were identified using polymerase chain reaction amplification, classical sequencing (Sanger), and multiplex ligation-dependent probe amplification.^10,11 Mutations were identified by comparison with the GenBank reference sequence for human OTC (GenBank entries: NG_008471.1, NP 000522.3, NM 000531.5, NC 000023.11).

Missense mutations were analyzed using different computational algorithms: CLUSTALW2 (http://www.clustal.org/clustal2/), SIFT (http://blocks.fhcrc.org/sift/SIFT.html), Polyphen2(http://genetics.bwh.harvard.edu/pph/), PoPMuSiC (http://babylone.ulb.ac.be/popmusic/), and SIFT Indel (http://siftdna.org/www/SIFT_indels2.html).

The study was approved by the Institutional Committee on Ethics of Research in Children and Adult Health. Informed consent was obtained prior to collection of biological samples.

Results and Discussion

A total of 14 patients with OTCD belonging to 11 unrelated families in Argentina were identified (Table 1). The phenotypic distribution was 28.5% (4/14) hemizygotes with neonatal-onset disease, 28.6% (4/14) hemizygotes with late-onset disease, and 42.8% (6/14) symptomatic heterozygous females. The age of onset was between 48 hours and 10 years (mean: 29.9 months).

Table 1
OTC Gene Mutations, Clinical Presentation, and Outcomes Identified in 14 Argentine Patients with OTCD.

Family	Patient	Gender	Presentation	Neurological Involvement	Nucleotide Change	Protein/Mutation Effect		Clinical Outcome/Remarks
I	1	Female	Late	Yes	-	Complete deletion		Decompensation during pregnancy
									and death
I	2	Female	Late	Yes	-	Complete deletion		Stable
I	3	Male	Neonatal	Yes	-	Complete deletion			1 2 son, death in neonatal period
II	4	Male	Late	No	c.2i6+ IG>A	Splice site errors		Stable
III	5	Male	Late	Yes	c.386G>A	p.Arg129His /splicing defects		Stable
IV	6	Female	Late	Yes	c.452T>G	p.Leu151Arg		Stable
V	7	Female	Late	Yes	c.533C>T	p.Thri78Met		Persistent vegetative state
V	8	Male	Neonatal	Yes	c.533C>T	p.Thr178Met		Death in neonatal period
VI	9	Female	Late	Yes	c.540+ IG>Aa	Splice site errors		Stable
VII	10	Male	Neonatal	Yes	c.540+ IG>Aa	Splice site errors		Death at 6 m, 2 brothers died in
									neonatal period
VIII	11	Male	Late	-	c.622G>A	p.Ala208Thr		Stable
IX	12	Male	Neonatal	Yes	c.697delGa	p.Leu232Leufs*I4		Death in neonatal period
X	13	Male	Late	Yes	c.829C>T	p.Arg277Trp		Death upon first disease crisis (I0
									years old)
XI	14	Female	Late	Yes	-	Exons I-9 duplication; exon I0		Death at 2 years old
							deletiona,b

• ^a
  Novel mutation.
• ^b
  De novo mutation.

Clinical manifestations varied between cases, with patients presenting 2 or more of the following signs and symptoms either in the acute or in the chronic presentation: drowsiness, lethargy, encephalopathy, convulsions, vomiting, behavior alterations, irritability, developmental delay, recurrent dysfunction of the liver or cholestasis, and coma. Compared to other population groups, our patients differed in their phenotypic distribution due to a greater number of symptomatic heterozygotes.^7,12,13 Regarding disease progression, all 4 OTCD males with the neonatal form died, while 3 of 4 males with late onset survived. Neonatal forms were not diagnosed in symptomatic females. Among these, and due to the severity of the hyperammonemic crises, 2 of 6 patients died and another one fell into a vegetative state. Previous reports have shown a survival of 80% to 90% in symptomatic heterozygotes and a generally favorable prognosis.¹⁴–¹⁶ In those patients who survived the hyperammonemic crisis, therapy consisted of low-protein diet, treatment with ammonia scavengers, and essential amino acid supplementation according to international recommendations and patient characteristics.

Biochemical findings (pooled data) for our patients with OTCD at disease onset included mean plasma ammonia: 547 µmol/L (range: 70-1500 µmol/L, normal range: <50 µmol/L), plasma glutamine: 800 µmol/L (range: 500-1300 µmol/L; normal range: 450-750 µmol/L), citrulline, and arginine within normal or decreased ranges and urinary orotic acid excretion in 13 of 14 cases.

Definitive diagnosis was obtained through genetic analysis, which revealed 10 different OTC gene mutations in the patient series, 3 of them previously unreported (Table 1). The identified mutations were uniquely found in each family, except for patients 9 and 10, who shared the same mutation although there was no known relationship between them.

The complete deletion of the OTC gene identified in family I results in total loss of OTC protein function in the hemizygous patient. The clinical presentation in the female carriers of this family was, as expected, extremely variable, given the X-linked inheritance of OTCD.⁴

The novel mutation c.697delG (family IX) results in a change in the reading frame, producing a premature stop codon at amino acid 14, thereby truncating the protein in the position 245, near its carboxyl terminus. Bioinformatic analysis by SIFT Indel (SIFT 4G Annotator version 2.3) suggests that the transcript is therefore exposed to nonsense-mediated decay, which makes this mutation equivalent to complete gene deletion because the messenger RNA (mRNA) is not translated. The program assigns a classification of 12 to this change, score obtained according to several factors such as the fraction of conserved bases of DNA, resulting amino acids, the maximum relative indel location, and its distance to the union with the exon, which predicts a highly harmful outcome (confidence of 0.858).¹⁷

The chromosomal rearrangement dup1-9/del10 described in patient 14 has not been reported. It entails a duplication in heterozygosis of the region between exons 1 and 9 plus a deletion of the contiguous region that includes exon 10 until the end of the gene, extending further into a region of the adjacent gene TSPAN7, whose disruption is associated with X-linked mental retardation. This alteration was demonstrated to be spontaneous. Even with specific treatment for OTCD, this girl had frequent decompensations due to infectious processes and developed a severe crisis that led to cerebral edema, cardiorespiratory arrest, and death.

Five previously described single-base substitutions in the OTC gene (c.386G>A; c.452T> G; c.533C>T; c.622G>A; c.829C>T)¹⁸ were also found in our patients (Table 1). The first is located on the last nucleotide of exon 4 and was classified initially as missense (p.Arg129His), although subsequent studies revealed that it partially affected the splicing process¹⁹; this mutation, identified in our study in a male with late disease onset, had been reported in both males and symptomatic females with severe or mild presentations. The other changes, all missense mutations, were analyzed using 3 computational algorithms (SIFT, Polyphen, and PoPMuSiC). Given the difficulty of assaying OTC enzymatic activity in patients, in silico studies are considered the most feasible and reliable way to analyze the severity of the mutations. After analyzing all the in silico results (Table 2), the c.533C>T mutation can be considered the most damaging of the series due to its strict conservation in all the analyzed species and the scores obtained in all the computational analyses. Moreover, it correlates precisely with the clinical manifestation of our patient, a seriously affected symptomatic carrier with a sibling that died perinatally.

Table 2
Bioinformatic Analysis of Missense Mutations in the OTC Gene.

			Polyphena				SIFTb				PoPMuSiCc
											AccSte	ΔΔG	Residual
Patient	Mutation		Score	Prediction			Score	Prediction			(%)	(kcal/mol)	Preservationd		Remarks
6	c.452T>G		0.995	Probably			0	Affects protein			1.55	2.29	Preserved in		Symptomatic heterozygous
		p.Leu151Arg			damaging				function					10 species		female
7/8	c.533C>T		0.999	Probably			0	Affects protein			1.97	0.14	Preserved in		Symptomatic heterozygous
		p.Thr178Met			damaging				function					11 species		female/male, early onset
10	c.622G>A		0.996	Probably			0	Affects protein			1.69	0.24	Preserved in 7		Male, late onset
		p.Ala208Thr			damaging				function					species
11	c.829C>T		0.997	Probably			0	Affects protein			1.95	1.34	Preserved in		Male, late onset
		p.Arg277Trp			damaging				function					11 species

• ^a
  Polymorphism Phenotyping: approach based on sequence and protein structure, assigns a score of 0 to benign variations, 0.5 for possibly damaging, and 1.0 for damaging.
• ^b
  Sorting Intolerant from Tolerant: approach based on evolution, the result of the analysis is a binary classification of 1 “tolerated” and 0 “not tolerated”.
• ^c
  Prediction of Protein Mutant Stability Changes: based on thermodynamic stability, characterized byfree energy of folding ΔG, and the solubility of variants. AccSte %: percentage of accessibility to the solvent of the mutated protein compared to the normal one; ΔΔG: Relative folding free energy variation expressed in kcal/mol.
• ^d
  According to amino acid sequence alignments using CLUSTALW2, the alignment for OTC gene was performed in 11 orthologous sequences.

According to previous reports and our own experience, mutations that completely abrogate the processing of OTC mRNA or the protein’s catalytic activity usually manifest with acute neonatal-onset hyperammonemia. That would be the case of the novel splicing mutation c.540+1G>A, to which we attribute the severe neonatal form observed in patient 10 and his siblings, who died at birth. Interestingly, the same mutation was also identified in patient 9, a seemingly unrelated heterozygous female with late disease onset. On the other hand, patient 4 (a male with a late form) also has a splice-site mutation (c.216+1G>A) but in this case it affects the genesis and processing of mature mRNA, in agreement with the original description of this mutation.¹⁸ Individuals with sequence variants that allow residual OTC activity may develop hyperammonemia at any time in life, while others remain asymptomatic. In patients with late-onset OTCD, acute hyperammonemia can be triggered by factors such as fasting status, infections, invasive medical procedures, or other environmental triggers resulting in increased protein catabolism and ammonia production.⁷

In conclusion, we discussed the clinical presentations, biochemical findings, disease outcomes, and mutation spectrum of a cohort of patients with OTCD from Argentina evaluated at a single center. Genotype identification allowed exact diagnosis and highlighted the importance of carrier testing for adequate genetic counseling. Among the 10 genetic defects described in our patient series, 3 are, to the best of our knowledge, novel and had not been reported until now. The identified mutations were validated with bioinformatic tools correlating genotype–phenotype, which allowed us to accurately predict, in most cases, disease presentation and progression.

As the most common genetic defect within the spectrum of urea cycle disorders, suspicion of OTCD, early confirmatory diagnosis, and prompt initiation of treatment are essential to avoid hyperammonemic crises that could cause irreversible neurological damage and even death.

Funding

• The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from Secretaría de Ciencia y Tecnología, Universidad Nacional de Córdoba and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.

References

• ¹
  Brusilow, SW, Horwich, AL. Urea cycle enzymes. In Scriver, C, Beaudet, A, Sly, W, Valle, D, eds. The Metabolic and Molecular Bases of Inherited Diseases. 8th ed. New York, NY: McGraw Hill; 2001.
• ²
  Summar, ML, Koelker, S, Freedenberg, D. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1-2):179-180.
• ³
  McCullough, BA, Yudkoff, M, Batshaw, ML, Wilson, JM, Raper, SE, Tuchman, M. Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype. Am J Med Genet. 2000;93(4):313-319.
• ⁴
  Scaglia, F., Zheng, Q., O'Brien, WE. An integrated approach to the diagnosis and prospective management of partial ornithine transcarbamylase deficiency. Pediatrics. 2002;109(1):150-152.
• ⁵
  Ah Mew, N, Simpson, KL, Gropman, AL. Urea cycle disorders overview. In Adam, MP, Ardinger, HH, Pagon, RA, Wallace, SE, Bean, LJH, Stephens, K, Amemiya, A, eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2017. 2003 Apr 29 [Updated 2017 Jun 22].
• ⁶
  Häberle, J., Boddaert, N., Burlina, A. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
• ⁷
  Caldovic, L, Abdikarim, I, Narain, S, Tuchman, M, Morizono, H. Genotype-phenotype correlations in ornithine transcarbamylase deficiency: a mutation update. J Genet Genomics. 2015;42(5):181-194.
• ⁸
  Duran, N . Amino acids. In Blau, N, Duran, N, Gibson, KM, eds. Laboratory Guide to the Methods in Biochemical Genetics. Berlín, Germany: Springer; 2008.
• ⁹
  Simmonds, HA, Duley, JA, Davies, PM. Analysis of purines and pyrimidines in blood, urine and other physiological fluids. In Hommes, F., ed. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. New York, NY: Wiley-Liss; 1991.
• ¹⁰
  García-Pérez, MA, Sanjurjo, P, Rubio, V. Demonstration of the spf-ash mutation in Spanish patients with ornithine transcarbamylase deficiency of moderate severity. Hum Genet. 1995;95(2):183-186.
• ¹¹
  Arranz, JA, Riudor, E, Marco-Marín, C, Rubio, V. Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential. J Inherit Metab Dis. 2007;30(2):217-226.
• ¹²
  Shao, Y, Jiang, M, Lin, Y. Clinical and mutation analysis of 24 Chinese patients with ornithine transcarbamylase deficiency. Clin Genet. 2017;92(3):318-322.
• ¹³
  Martín-Hernández, E, Aldámiz-Echevarría, L, Castejón-Ponce, E. Urea cycle disorders in Spain: an observational, cross-sectional and multicentric study of 104 cases. Orphanet J Rare Dis. 2014;9:187.
• ¹⁴
  Brassier, A, Gobin, S, Arnoux, JB. Long-term outcomes in Ornithine Transcarbamylase deficiency: a series of 90 patients. Orphanet J Rare Dis. 2015;10:58.
• ¹⁵
  Nakamura, K, Kido, J, Mitsubuchi, H, Endo, F. Diagnosis and treatment of urea cycle disorder in Japan. Pediatr Int. 2014;56(4):506-509.
• ¹⁶
  Summar, ML, Dobbelaere, D, Brusilow, S, Lee, B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97(10):1420-1425.
• ¹⁷
  Hu, J., Ng, PC. Predicting the effects of frameshifting indels. Genome Biol. 2012;13(2):R9.
• ¹⁸
  Yamaguchi, S, Brailey, LL, Morizono, H, Bale, AE, Tuchman, M. Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene. Hum Mutat. 2006;27(7):626-632.
• ¹⁹
  Rivera-Barahona, A, Sánchez-Alcudia, R, Viecelli, HM. Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man. Plos One. 2015;10(4):e0122966.

Publication Dates

• Publication in this collection
  2018

History

• Received
  01 Jan 2018
• Accepted
  26 July 2018